Daihan Pharmaceutical (023910.KQ) Earnings Analysis
Daihan Pharmaceutical (023910.KQ) has no confirmed upcoming earnings date. Trailing P/E 5.65.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 023910.KQ next report earnings?
No confirmed upcoming earnings date is currently scheduled for 023910.KQ. This page updates as the calendar is published.
023910.KQ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | 1,186.82 KRW | n/a | n/a | n/a |
| 2026-03-06 | 862.87 KRW | n/a | n/a | n/a |
023910.KQ valuation and analyst view
| Trailing P/E | 5.65 |
|---|---|
| Trailing EPS | 4,586.6 KRW |
| Price / book | 0.51 |
| Dividend yield | 3.47% |
| Market cap | 151.41B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Daihan Pharmaceutical (023910.KQ)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 023910.KQ. This page updates as the calendar is published.
Did 023910.KQ beat earnings last quarter?
Consensus estimate data was not available for 023910.KQ's 2026-05-15 report.
What is 023910.KQ's current P/E ratio and EPS?
023910.KQ trades at a trailing P/E of 5.65 on trailing EPS of 4586.60013583815 KRW.
What do analysts rate 023910.KQ?
023910.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.